ACE Report Cover
AAOS 2025: Vancomycin Bier Block Administration Vs Intravenous Prophylaxis
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
GENERAL ORTHOPAEDICS
AAOS 2025: Vancomycin Bier Block Administration Vs Intravenous Prophylaxis

Tissue Concentrations of Vancomycin Achieved With Bier Block Administration Versus Intravenous Prophylaxis in Upper Extremity Surgery: A Randomized Controlled Trial

Contributing Authors

KJ Renfree N Hinckley M Klanderman

Twenty patients undergoing upper extremity reconstructive surgery were randomized to receive either regional IV perfusion of vancomycin (125 mg in 50 ml saline) (n=10) or systemic IV vancomycin (1 g) (n=10). The primary outcome of interest was the difference in vancomycin concentration in bone and fat tissue between the groups. Secondary outcomes of interest included tissue concentrations at various time points and complications related to drug delivery. Outcomes were assessed at 5–10 minutes, 20–25 minutes after skin incision, and at wound closure. Overall, the results of the study revealed that tissue concentrations of vancomycin were significantly higher in the regional IV perfusion group across all time points, with no observed complications in either group. These findings suggest Bier block administration may offer a safer and more effective alternative to systemic prophylaxis in upper extremity surgery.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. AAOS 2025: Vancomycin Bier Block Administration Vs Intravenous Prophylaxis. ACE Report. 2025;307(3):87. Available from: https://myorthoevidence.com/AceReport/Show/aaos-2025-vancomycin-bier-block-administration-vs-intravenous-prophylaxis

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report